Infant respiratory distress syndrome

Innovation Pharmaceuticals Provides Update on U.S. Patent Applications Covering Use of Brilacidin in Inflammatory Bowel Diseases, Coronaviruses and Fungal Diseases

Retrieved on: 
Wednesday, June 21, 2023

Brilacidin is a Host Defense Protein-mimetic drug candidate with broad-spectrum immunomodulatory and antimicrobial properties.

Key Points: 
  • Brilacidin is a Host Defense Protein-mimetic drug candidate with broad-spectrum immunomodulatory and antimicrobial properties.
  • The Company out-licensed Brilacidin in UP/UPS to Alfasigma S.p.A. Brilacidin has also been evaluated in Phase 2 testing in moderate-to-severe hospitalized cases of COVID-19 (by intravenous delivery), with beneficial treatment effects observed in patient subgroups.
  • A separate patent application has been submitted to the USPTO for use of Brilacidin in fungal diseases.
  • Additional in vivo testing in efficacy models against two hard-to-treat fungal pathogens is scheduled for 3Q2023.

Chiesi USA Announces Publication of Health Economics Analysis of Selective Early Rescue Surfactant Administration vs. Standard Surfactant Administration for Premature Infants with Respiratory Distress Syndrome

Retrieved on: 
Tuesday, November 29, 2022

CARY, N.C., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare group (Chiesi Group), today announced the publication of an article describing a health economic model comparing selective early rescue surfactant administration versus standard surfactant administration for infants with respiratory distress syndrome (RDS).

Key Points: 
  • CARY, N.C., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare group (Chiesi Group), today announced the publication of an article describing a health economic model comparing selective early rescue surfactant administration versus standard surfactant administration for infants with respiratory distress syndrome (RDS).
  • Early selective surfactant administration, such as use of the INtubation SURfactant Extubation (INSURE)* technique was compared to a base case of standard surfactant administration via endotracheal intubation and mechanical ventilation.
  • CUROSURF Intratracheal Suspension is a surfactant indicated for the rescue treatment, including the reduction of mortality and pneumothoraces, of respiratory distress syndrome (RDS) in premature infants.
  • The authors conclusions suggest that selective early rescue surfactant administration strategies are associated with a lower healthcare burden in premature infants with RDS.

Global Neonatal Critical Care Equipment Market (2022 to 2030) - Size, Share & Trends Analysis Report - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 14, 2022

The Neonatal Intensive Care Unit (NICU) provides treatment to premature infants and those having breathing problems, anemia, heart defects, and other problems requiring critical care.

Key Points: 
  • The Neonatal Intensive Care Unit (NICU) provides treatment to premature infants and those having breathing problems, anemia, heart defects, and other problems requiring critical care.
  • Such situations have amplified the production of neonatal critical care equipment to ensure that premature babies are protected from the virus.
  • North America dominated the neonatal critical care equipment market in 2021 due to the strategic presence of major players and high healthcare expenditure and measures adopted by organizations to improve healthcare for neonatal.
  • The manufacturers of neonatal critical care equipment are undertaking research and development activities to provide innovative products, to cater to the increasing demand for NICUs globally.

Windtree Announces Results from Its Phase 2 Study of Lucinactant for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) and Lung Injury

Retrieved on: 
Tuesday, March 22, 2022

Surfactant deficiency is known to contribute to the pathophysiology of ARDS, respiratory failure, and lung injury in patients on mechanical ventilation.

Key Points: 
  • Surfactant deficiency is known to contribute to the pathophysiology of ARDS, respiratory failure, and lung injury in patients on mechanical ventilation.
  • The Phase 2 trial was designed to assess feasibility, safety, and tolerability of administration of reconstituted lyophilized lucinactant in these critically ill patients.
  • The multicenter, single-arm study enrolled 20 critically ill patients who were intubated and on mechanical ventilation due to severe COVID-19 associated ARDS.
  • Patients received lucinactant as a liquid via the endotracheal tube assessing safety and tolerability of the administration procedure and of the drug.

Respiratory Distress Syndrome Global Market Insight, Epidemiology and Market Forecast to 2032 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 16, 2022

The "Respiratory Distress Syndrome - Market Insight, Epidemiology and Market Forecast -2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Respiratory Distress Syndrome - Market Insight, Epidemiology and Market Forecast -2032" report has been added to ResearchAndMarkets.com's offering.
  • The report delivers an in-depth understanding of the Respiratory Distress Syndrome, historical and forecasted epidemiology as well as the Respiratory Distress Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
  • The Respiratory Distress Syndrome market report provides current treatment practices, emerging drugs, Respiratory Distress Syndrome market share of the individual therapies, current and forecasted Respiratory Distress Syndrome market Size from 2019 to 2032 segmented by seven major markets.
  • The Report also covers current Respiratory Distress Syndrome treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Windtree to Present at the Ladenburg Thalmann 2021 Healthcare Conference (Virtual)

Retrieved on: 
Wednesday, July 7, 2021

WARRINGTON, Pa., July 07, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that Craig Fraser, President and Chief Executive Officer, will present a company overview and be available for 1x1 meetings at the following upcoming conference:

Key Points: 
  • WARRINGTON, Pa., July 07, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that Craig Fraser, President and Chief Executive Officer, will present a company overview and be available for 1x1 meetings at the following upcoming conference:
    Windtree Therapeutics, Inc. is advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders to treat patients in moments of crisis.
  • Using new clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate istaroxime being developed as a first-in-class treatment for acute heart failure and early cardiogenic shock in heart failure.
  • Windtree has also focused on developing AEROSURF as a non-invasive surfactant treatment for premature infants with respiratory distress syndrome, and is facilitating transfer of clinical development of AEROSURFto its licensee inAsia, Lee's HK, while Windtreeevaluates other uses for its synthetic KL4 surfactant for the treatment of acute pulmonary conditions including lung injury due to viral, chemical and radiation induced insults.
  • Also, in its portfolio is rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.

Results of Biomarck Clinical and Preclinical Studies of BIO-11006 in ARDS to be Presented at the 2021 ARDS Drug Development Summit

Retrieved on: 
Wednesday, July 7, 2021

At 28 days there were 7 deaths (37%) in the placebo arm and 4 deaths (21%) in the BIO-11006 treatment arm.

Key Points: 
  • At 28 days there were 7 deaths (37%) in the placebo arm and 4 deaths (21%) in the BIO-11006 treatment arm.
  • Treatment with BIO-11006 prevented development of ARDS, reversed established ARDS and prevented neutrophil influx into the lungs.
  • It is hoped that these results can now be repeated in a larger clinical trial currently being planned.
  • Inhibiting MARCKS with our peptides reduces the adverse effects of inflammation, including acute respiratory distress syndrome (ARDS) and cytokine storm.

Acute Respiratory Distress Syndrome (ARDS) Pipeline Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 7, 2021

The "Acute Respiratory Distress Syndrome (ARDS) - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Acute Respiratory Distress Syndrome (ARDS) - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Acute respiratory distress syndrome (ARDS) - Pipeline Insight, 2021" report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Acute respiratory distress syndrome (ARDS) pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Acute respiratory distress syndrome (ARDS) R&D.
  • Acute respiratory distress syndrome (ARDS) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Q BioMed Inc. Discusses Progress of COVID-19 Therapeutic and $30 Million Potential Investment with The Stock Day Podcast

Retrieved on: 
Wednesday, June 23, 2021

Phoenix, Arizona--(Newsfile Corp. - June 23, 2021) - The Stock Day Podcast welcomed Q BioMed Inc. (OTCQB: QBIO) ("the Company"), a biotech acceleration and commercial stage company.

Key Points: 
  • Phoenix, Arizona--(Newsfile Corp. - June 23, 2021) - The Stock Day Podcast welcomed Q BioMed Inc. (OTCQB: QBIO) ("the Company"), a biotech acceleration and commercial stage company.
  • CEO of the Company, Denis Corin, joined Stock Day host Everett Jolly.
  • "Q BioMed is what we like to call a biotechnology development and acceleration company," said Corin.
  • "The most prominent of those is a COVID-19 therapeutic," he shared, adding that the therapeutic is designed to treat ARDS (acute respiratory distress syndrome).

Athersys Reports That Healios Has Completed Enrollment in the ONE-BRIDGE Study of MultiStem® for Acute Respiratory Distress Syndrome in Japan

Retrieved on: 
Wednesday, March 31, 2021

(Healios) has completed enrollment in the ONE-BRIDGE study in Japan evaluating MultiStem (invimestrocel) in patients with acute respiratory distress syndrome (ARDS) caused by pneumonia.

Key Points: 
  • (Healios) has completed enrollment in the ONE-BRIDGE study in Japan evaluating MultiStem (invimestrocel) in patients with acute respiratory distress syndrome (ARDS) caused by pneumonia.
  • Healios intends to analyze and evaluate the data after the follow-up period and will make further announcements, as appropriate.
  • In the United States, Athersys is conducting its own clinical study evaluating MultiStem cell therapy for the treatment of ARDS, the MACOVIA trial.
  • Acute respiratory distress syndrome (ARDS) is a serious immunological and inflammatory condition characterized by widespread inflammation in the lungs.